Prelude Therapeutics Inc
PRLDNext catalyst
PRT3789
Advanced Solid Tumor
Get an email about PRLD's next catalysts
Track Prelude Therapeutics (PRLD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
2 upcoming, 1 past
PRLD Reports Financial Results
Filed: 2026-11-16 AccNo: 0001193125-26-462029 Size: 21 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
SourcePRT3789 Phase 2 Est. Readout
Primary completion for PRT3789 trial (NCT06682806) in Advanced Solid Tumor
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PRT3789 | Phase 2 | Advanced Solid Tumor | - | - |
Frequently asked questions
What is in Prelude Therapeutics Inc's drug pipeline?β
CatalystAlert tracks 1 drug candidate in Prelude Therapeutics Inc's (PRLD) pipeline across Phase 2. Its lead program is PRT3789 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Prelude Therapeutics Inc's next FDA catalyst?β
Prelude Therapeutics Inc's (PRLD) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRLD biotech catalysts?β
Add PRLD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Prelude Therapeutics Inc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
